Effects of Oral PLAP on Food Consumption, Body Weight, Visceral Fat, and Triglycerides in Already Obese and Diabetic Mice; In each case n=7

Beginning on day 17 and continuing through day 40, Group 1 continued on SD, while Groups 2 through 4 (already obese type 2 diabetic) remained on high fat diet. During this period, mice in Group 1 received only water for the next 23 days, while on days 22, 27, 32, and 35 mice in Groups 3 and 4 also received 60 μg PLAP/ml and 240 μg PLAP/ml, respectively, from 9 p.m. to 9 a.m. The results indicate that in obese diabetic mice orally administered highly purified (98%) PLAP strongly reduces gains in body weight, visceral fat, and triglycerides without affecting food consumption.

In addition:

● Systemic PLAP (Recombinant or ~98% Purified), Applied Once per Week s.c. or i.v. at Doses of 0.04-0.1 mg/Mouse to Obese or Non-Obese Mice (Younger or Older), Similarly Reduced Excess Visceral Fat by 80-90% with Exerting Smaller Effects on General Obesity (n=7).

● In Obese Diabetic Mice, the Above Doses of Systemic PLAP and Oral PLAP Similarly Reduced Elevated Blood Glucose by 60-70%, Serum Insulin by ~90%, Blood Triglycerides by ~90-100%, and LDL-Cholesterol by 50-60% (in each case n=7).